Title: Pathogenicity of the omicron variant strain comparison with delta variant strain and seasonal influenza in Japan: Updated until June 2022.

Junko Kurita[1],Tamie Sugawara[2], Yasushi Ohkusa[2]

[1] Department of Nursing, Faculty of Sports & Health Science, Daitoubunka University, Higashimatsuyama,Saitama, Japan

[2] Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan

Keywords: excess mortality; COVID-19; all cause death; stochastic frontier estimation; NIID model; Tokyo; Japan

*) Correspondence to:

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

Tamie Sugawara tammy@nih.go.jp

ICMJE Statement

Contributors TS was responsible for the organization and coordination of the study. JK was the chief investigator and responsible for the data setting. YO developed the estimation model. All authors contributed to the writing of the final manuscript.

Abstract

Background: No remarkable mortality attributable to COVID-19 confirmed by PCR test has been observed in Japan.

Object: We sought to quantify excess mortality using the National Institute of Infectious Diseases (NIID) model.

Method: We applied the NIID model to deaths of all causes from 1987 up through the June2022 for the whole of Japan and up through March, 2022 for Tokyo.

Results: Results in Japan show huge number of excess mortality, up to 10 thousands in the two months, in August and September, 2021, when delta variant strain prevailed. Moreover, we found the largest number of excess mortality in a month since COVID-19 emerging in February and March 2022 in the whole of Japan, when one month later since the number of newly confirmed patients with omicron variant strain reached the peak.

Discussion and Conclusion: The result in February and March 2022 may indicate the pathogenicity of the omicron variant strain was comparable delta variant strain and stronger than seasonal influenza.

1. Introduction

To date, excess mortality has mainly been used to assess the social effects of influenza activity [1–6]. However, since the emergence of COVID-19, excess mortality attributable to COVID-19 has been attracting attention [7] as a measure of the total effects of the disease because it can reflect cases which have not been identified as polymerase chain reaction (PCR) positive. Especially in Japan, PCR tests administered per capita have been few. Therefore, concern has arisen about the possibility that some deaths caused by COVID-19 have not been recognized heretofore. Moreover, excess mortality related to COVID-19 might be expected to contribute to evaluation of vaccine effects. For these evaluations, the estimated excess mortality without the effects of a vaccine should be regarded as a baseline. Nevertheless, no such a trial has been undertaken to date. This study might be the first trial to measure that figure in Japan.

As of the end of 2021, the COVID-19 outbreak showed about 1.73 million patients and about 1.84 thousand deaths from the outbreak have been reported in Japan. Although Japan has about one third of the population of the U.S., these figures are vastly different in scale from those of the U.S., which has reported 54.8 million cases of morbidity and 826 thousand deaths [8]. In light of the much lower number of patients in Japan, some criticism has arisen that low PCR testing rates might have led to the lower number of documented patients [9]. In this sense, one might regard the number of deaths as reflecting the actual situation in Japan, but with no testing-related bias.

Concerning deaths, the case-fatality rate (CFR) is about 5%. In fact, the CFRs in both countries are not much different. The lower PCR testing in Japan might be related to some problems. Therefore, we specifically examined excess mortality attributable to COVID-19 in Japan, irrespective of the cause of death.

In Japan, excess mortality was estimated using the National Institute of Infectious Diseases (NIID) model [10], which has been the official procedure for more than ten years. It was applied to two data sources: the national monthly deaths of all causes and the respective weekly pneumonia and influenza deaths in the 21 largest cities and their total. The latter is published regularly in Japanese during the influenza season as https://www.niid.go.jp/niid/ja/flu-m/2112-idsc/jinsoku/131-flu-jinsoku.html. Unfortunately, that publication ceased in March 2020 because it is intended for influenza. The first peak in Japan was April 3, 2020[11]: excess mortality cannot be detected until March. Instead, we applied NIID model to the all causes of death in the whole of Japan to evaluate impact of the outbreak of COVID-19.

2. Method

Excess mortality is defined as the difference between the actual number of deaths and an epidemiological threshold. The epidemiological threshold is defined as the upper bound of the 95% confidence interval (CI) of the baseline. The baseline is defined as the number of deaths that are likely to have occurred if an influenza outbreak had not occurred. Therefore, if the actual deaths are fewer than the epidemiological threshold, then excess mortality is not inferred.

The data used for this study were monthly deaths of all causes from 1987 through the June 2022 for the whole of Japan and December 2021 for Tokyo [12]. NIID model, the Stochastic Frontier Estimation [13–19], is presented as

$$log\ D_t=\alpha+\beta T_t+\gamma T_t^2+\Sigma\eta_i M_{it}+\varepsilon_t \quad \text{and} \qquad (1)$$

$$\varepsilon_t=v_t+|\omega_t|\ , \qquad (2)$$

where D_t represents all causes of death in month/year t, T_t denotes the linear time trend, and M_{it} is the dummy variable for a month, which is one if t is the i-th month and otherwise zero. Moreover, v_t and ω_t are stochastic variables as $v_t \sim N(0, \mu^2)$ and $\omega_t \sim N(0,\xi^2)$; they are mutually independent. Although v_t represents stochastic disturbances, ω_t denotes non-negative deaths attributable to influenza. These disturbance terms in this model are parameterized by two parameters: ξ/μ and $(\mu^2+\xi^2)^{0.5}$. If the null hypothesis $\xi/\mu=0$ is not rejected, then the Stochastic Frontier Estimation model is inappropriate.

Study areas were the whole of Japan and its capital, Tokyo. Study period foe estimation was from 1987 to the June 2022 for the whole of Japan and up through March, 2022 for Tokyo. We adopted 5% as significant level.

3. Results

Table 1 summarized the estimation results in the whole of Japan and Table 2 for Tokyo. Figure 1 presents observed deaths, the estimated baseline, and its threshold in Japan. Figure 2 specifically depicts the period since emerging COVID-19. We found 12 and 104 excess mortality in August and October, 2020, and 260, 135, 4106, 5853 and 584 in May, June, August, September and October, 2021. In February ,March, May and June 2022, 9705, 5396, 337 and 748 excess mortality was observed, respectively. These were 0.0, 0.1, 0.2, 0.1, 3.8, 5.5, 0.5, 7.8, 4.2, 0.3 and 0.7% of the baseline. In total, 27240 excess mortality were observed since 2020 until June 2022..

Figure 3 and 4 showed the estimated result in Tokyo. We found 595 excess mortality in August and 150 excess mortality in September 76 in October, 458 in December, 2020, 44 in January, 60 in April, and 762, 942 and 130 in August to October, 2021 which were 6.3, 1.7, 0.8, 4.1, 0.4, 0.6, 8.0, 10.2 and 1.3 % of the baseline. Additionally, there were1427 and 1201 excess morality in February and March, 2022. It means 13% and 11% of the baseline and it was largest excess mortality in Tokyo during the COVD-19 pandemic.

4. Discussion

This study applied the NIID model to all causes of death to detect excess mortality attributable to COVID-19. We found huge number of excess mortality in August and September, 2021 up to about 10 thousands in the two months in the whole of Japan. We supposed it caused by delta variant strain. At the same time, only 2464 PCR-confirmed death were reported, which was less than quarter of excess mortality. Especially, in Tokyo, we found substantial excess mortality which was approximately 8 and 10% of the baseline at that time.

Moreover, 9705 and 5396 excess mortality in the whole of Japan in February and

March, 2022. It was supposed to cause by omicron variant strain. The number of excess mortality at that time was largest number in a month since COVID-19 emerging. Its ratio to base lines in February 2022, 7.8%, was also largest since 2020. However, concerning about total number of excess mortality over several months by the dominated strain, delta variant strain had larger than ten thousands and thus omicron variant strain has almost comparable but slightly smaller than delta variant strain.

On the other hand, in Tokyo, the highest excess mortality in a month was recorded in February, 2022 which was supposed to due to omicron variant strain. Conversely, there were 1834 excess mortality in Tokyo since August to October, 2021 when delta variant strain had prevailed. It is not sure about excess mortality in March in Tokyo, total number of excess mortality due to omicron variant strain might be smaller due to delta variant strain even in Tokyo.

Recently, international comparison of excess mortality caused by COVID-19 was published [20]. In this article, it reported 112 thousands excess mortality in Japan. It was about six times larger than the number of death confirmed COVID-19 infection. Conversely, we found about 27 thousands excess mortality. It was slightly larger than the number of death confirmed COVID-19 infection, however, it was almost comparable. In this sense, the international comparison may underestimate the baseline and overestimate excess mortality. It is well known bias in the careless estimation foe excess mortality

[21]. Hence, international comparison might be less precise estimation than this study. Overestimation of excess mortality might mislead to inappropriate policy or counter measures and inflate its disease burden.

5. Conclusion

We found substantial excess mortality since the outbreak of COVID-19 had emerged in the whole of Japan in the period between August to October, 2021, up to 10 thousands when delta variant strain prevailed. Moreover, we found the largest excess mortality in a month in February, 2020 and it was supposed to cause by omicron variant strain. It may indicate the pathogenicity of the omicron variant strain was comparable delta variant strain and stronger than seasonal influenza.

The present study is based on the authors' opinions: it does not reflect any stance or policy of their professionally affiliated bodies.

6. Acknowledgement

We acknowledge Dr. Nobuhiko Okabe, Kawasaki City Institute for Public Health, Dr.Kiyosu Taniguchi, National Hospital Organization Mie National Hospital, and Dr.Nahoko Shindo, WHO for their helpful support.

7. Conflict of interest

The authors have no conflict of interest to declare.

8. Ethical considerations

All information used for this study was published on the web site of MHLW [12]. Therefore, no ethical issue is presented.

9. References

1) Lin HC, Chiu HF, Ho SC, Yang CY. Association of influenza vaccination and reduced risk of stroke hospitalization among the elderly: a population-based case-control study. Int J Environ Res Public Health 2014; 11: 3639-49.

2) Asghar Z, Coupland C, Siriwardena N. Influenza vaccination and risk of stroke: Self-controlled case-series study. Vaccine. 2015; 33: 5458-63.

3) Riedmann EM. Influenza vaccination reduces risk of heart attack and stroke. Hum Vaccin Immunother 2013; 9: 2500.

4) Kwok CS, Aslam S, Kontopantelis E, Myint PK, Zaman MJ, Buchan I, Loke YK, Mamas MA. Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies. Int J Clin Pract. 2015;69:928-37.

5) Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, Vogel AB, Marti HH, Al-Abed Y, Planz O, Schwaninger M. Influenza virus infection aggravates stroke outcome. Stroke. 201142 783-91.

6) Assad F, Cockburn WC, Sundaresan TK. Use of excess mortality from respiratory diseases in the study of influenza. Bull WHO 1973; 49: 219-33.

7) US Center for Disease Control and Prevention. Excess Deaths Associated with COVID-19. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm [accessed on July 15, 2022]

8) Japan Times. Japan's daily PCR test capacity tops 20,000. https://www.japantimes.co.jp/news/2020/05/16/national/japans-daily-pcr-test-capacity-20000/#.XuAwImeP6AA [accessed on January 15, 2022]

9) World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ [accessed on January 12,2022]

10) Sugawara T, Ohkusa Y. Comparison of Models for Excess Mortality of Influenza Applied to Japan. Journal of Biosciences and Medicines, 2019, 7, 13-23. doi:10.4236/jbm.2019.76002

11) Kurita J, Sugawara T, Ohkusa Y. Mobility data can explain the entire COVID-19 outbreak course in Japan. medRxiv 2020.04.26.20081315; doi: https://doi.org/10.1101/2020.04.26.20081315

12) Ministry of Health, Labour and Welfare. Preliminary statistics on

demographicshttps://www.mhlw.go.jp/toukei/list/81-1a.html (in Japanese) [accessed on January 16, 2022]

13) Aiger AD, Lovell K, Schmitidt P. Formulation and estimation of stochastic frontier production function models. Journal of Econometrics 1977; 21-37.

14) Jondrow J, Lovell K, Materov S, Schmidt P. On the estimation of technical inefficiency in the stochastic frontier production function model. Journal of Econometrics 1982; 233-9.

15) Li T, Rosenman R. Cost inefficiency in Washington Hospitals: A stochastic frontier approach using panel data, Health Care Management Science 2001; 4: 73-81.

16) Newhouse JP. Frontier Estimation: How useful a tool for health economics? Journal of Health Economics 1994; 13: 317-22.

17) Shelton Brown H. Managed care and technical efficiency. Health Economics. 2003; 12: 149-58.

18) Jacobs R. Alternative methods to examine hospital efficiency: Data envelopment analysis and stochastic frontier analysis. Health Care Management Science. 2001; 4: 103-15

19) Rosko MD. Cost efficiency of US hospitals: A stochastic frontier approach. Health Economics. 2001; 539-51.

20) COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022 ;399:1513-36.

21) Sugawara T, Ohkusa Y. Comparison of Models for Excess Mortality of Influenza Applied to Japan. Journal of Biosciences and Medicines, 2019, 7, 13-23. doi:10.4236/jbm.2019.76002

Table 1 NIID Model estimation results since 1987 until June 2022 in Japan

Explanatory variables	Estimated coefficients	*p*-value
Constant	11.12	<0.0004
Time trend	0.001537	<0.0004
Time trend ^{2}	0.0000009763	0.423
January	0.07075	<0.0004
February	-0.05631	<0.0004
March	-0.01671	0.053
April	-0.1027	<0.0004
May	-0.1247	<0.0004
June	-0.2126	<0.0004
July	-0.1776	<0.0004
August	-0.1710	<0.0004
September	-0.2083	<0.0004
October	-0.1197	<0.0004
November	-0.08768	<0.0004
ξ/μ	2.386	<0.0004
$(\mu^2+\xi^2)^{0.5}$	0.04934	<0.0004

Note: The number of observations was 419. The estimated log likelihood was 915.5. ξ^2 denotes the variance of the non-negative disturbance term. μ^2 is the variance of the disturbance term.

Table 2 NIID Model estimation results since 1987 until March 2022 in Tokyo

Explanatory variables	Estimated coefficients	*p*-value
Constant	8.55	<0.0004
Time trend	0.00186	<0.0004
Time trend ^{2}	$-0.726*10^{-6}$	0.001
January	0.0759	<0.0004
February	0.137	<0.0004
March	0.0292	0.015
April	0.0479	<0.0004
May	-0.0271	0.111
June	-0.0584	<0.0004
July	-0.111	<0.0004
August	-0.0664	<0.0004
September	-0.0719	<0.0004
October	-0.108	<0.0004
November	-0.0253	0.102
ξ/μ	2.44	<0.0004
$(\mu^2+\xi^2)^{0.5}$	0.0 684	<0.0004

Note: The number of observations was 417. The estimated log likelihood was 817.9. ξ^2 denotes the variance of the non-negative disturbance term. μ^2 is the variance of the disturbance term.

Figure 1: Observations of the estimated baseline and threshold since 1987 until June 2022 in Japan

(persons)



Month/Year

Note: The blue line represents observations. The red line represents the estimated baseline. The green line shows its threshold.

Figure 2: Observation of the estimated baseline and threshold since January 2020 in Japan (persons)



Month/Year

Note: The blue line represents observations. The red line represents the estimated baseline. The green line shows its threshold.

Figure 3: Observations of the estimated baseline and threshold since 1987 until March, 2022 in Tokyo

(persons)



Month/Year

Note: The blue line represents observations. The red line represents the estimated baseline. The green line shows its threshold.

Figure 4: Observation of the estimated baseline and threshold since May 2019 until March, 2022 in Tokyo

(persons)



Month/Year

Note: The blue line represents observations. The red line represents the estimated baseline. The green line shows its threshold.